Infiltrating T lymphocytes are found in many malignancies, but they appear to be mostly anergic and do not attack the tumor, presumably because of defective T-cell activation events. Recently, we described a strategy for the tumor-specific polyclonal activation of tumor-resident T lymphocytes based on the in situ production of recombinant bispecific antibodies (bsAbs) by transfected nonhematological cell lines. Here, we have constructed a novel HIV-1-based lentiviral vector for efficient gene transduction into various human hematopoietic cell types. Several myelomonocytic and lymphocytic cell lines secreted the anticarcinoembryonic antigen (CEA) Â anti-CD3 diabody in a functionally active form with CD3 þ T-cell lines being the most efficient secretors. Furthermore, primary human peripheral blood lymphocytes (PBLs) were also efficiently transduced and secreted high levels of functional diabody. Importantly gene-modified PBLs significantly reduced in vivo tumor growth rates in xenograft studies. These results demonstrate, for the first time, the utility of lentiviral vectors for sustained expression of recombinant bsAbs in human T lymphocytes. Such T lymphocytes, transduced ex vivo to secrete the activating diabody in autocrine fashion, may provide a promising route for a gene therapy strategy for solid human tumors.
Introduction
The cellular arm of the immune system is the principal defense mechanism by which the body rejects foreign, infected or transformed tissue. 1 However, cell-based immunotherapy approaches have limitations. Most of the infiltrating lymphocytes are not prepared to confront the tumor as tumor cells themselves generally provide poor targets for immunological responses. In many cases, surface expression of major histocompatibility complex (MHC) molecules is downregulated or lost altogether and changes in peptide transporter or proteasome functions 2 provide for poor peptide display on the MHC. These observations have led to new approaches to try to redirect T-cell responses to important native antigens (Ags) expressed on the tumor cell surface. These include the genetic manipulation of the recognition specificity of T lymphocytes by grafting the recognition specificity of an antibody (Ab) onto the signaling components of the TCR/CD3 complex to create a chimeric immune receptor (CIR) 3 and the use of bispecific antibodies (bsAbs). 4 BsAbs are nonnatural immunoglobulin-based molecules that contain two distinct binding specificities. 4 BsAbs redirect or enhance effector activity of lymphocytes or phagocytes towards target cells by binding to cell activation molecules with one domain and to specific surface Ags on target cells with the other. 5 The potential of bsAbs in cancer therapy has been extensively proved in a variety of in vitro and in vivo models, and several different bsAbs have been tested in clinical trials. 4 Nevertheless, the therapeutic potential of exogenously administered bsAbs is limited by their short half-life and their poor accessibility to tumor sites. Moreover, systemic administration of bsAbs can also lead to serious side effects owing to the acute release of cytokines. 6 These problems can be bypassed by the in situ production of bsAb molecules at the tumor site by cells that have preferential tumor-targeting properties. 5 In fact, we have demonstrated proof-of-principle for a novel genetic strategy of T-cell activation by paracrine secretion of recombinant bsAbs. 7 Bispecific aCEA (carcinoembryonic antigen) Â aCD3 diabodies were secreted at high levels by transfected nonhemaopoietic cell lines and were able to efficiently activate peripheral blood lymphocytes (PBLs) to proliferate and eliminate CEA-expressing tumor cells.
However, a strategy of autocrine secretion of recombinant antitumor diabodies by PBLs themselves would be preferable for clinical application. Such 'self-arming' T lymphocytes might be generated ex vivo but this will require a system for gene transduction that allows longterm, nontoxic gene expression in hematopoietic cells with tumor-homing ability. Here, we demonstrate that the diabody gene can be efficiently transduced into human PBLs by a lentiviral vector and that the gene modified lymphocytes secrete the aCEA Â aCD3 diabody causing T-cell activation and tumor growth inhibition in vivo.
Materials and methods

Antibodies and reagents
The monoclonal antibodies (mAbs) used included: OKT3 (antihuman CD3e, Ortho Biotech, Bridgewater, NJ) Leu-28 (antihuman CD28, Beckton-Dickinson, San Jose´, CA); 85A12 (antihuman CD66e; Serotec, Oxford, UK); and 9E10 (anti-myc, Sigma Biosciences, St Louis, MO). For direct staining, the following PE-or electron coupled dye (ECD)-conjugated antihuman CD3e (UCHT1), CD4 (SFC112T4D11), CD8 (B9.11), CD14 (RM052), CD19 (J4.119) and CD56 (NKH-1) mAbs (Beckman Coulter, Miami, FL) were used. Horse radish peroxidase-conjugated goat antimouse immunoglobulin (Ig)G (Fc specific) polyclonal Ab and human interleukin-2 (IL-2) were from Sigma Biosciences. Recombinant human fibronectin CH-296 fragment (Retronectin) was from Takara Bio Inc. (Otsu, Shiga, Japan). 22 To construct the plasmid pRRL.dAb. IRES.EGFP, the BglII-XhoI fragment derived from the plasmid pBEL3 7 was ligated into the BamHI/XhoI digested backbone of plasmid pRRL.IRES.EGFP. Lentiviral particles were produced by cotransfection of 293T cells through calcium phosphate precipitation. The cells (6 Â 10 6 ) were transfected with 14.1 mg of transducing vector (pRRL.IRES.EGFP or pRRL.dAb.IRES.EGFP), 9 mg of pMDLg/pRRE, 3.45 mg of pRSVrev and 4.71 mg of pMD.G in the presence of 25 mM chloroquine (Sigma Biosciences). The medium was replaced 8 h after transfection and then every 24 h for 2 days. Conditioned-medium was collected, passed through a 0.45 mm-pore filter, ultracentrifugated (24.500 r.p.m. for 2 h), aliquoted and immediately frozen at À801C. . Reverse-transcriptase activity in cellfree supernatant (SN) of infected cells was determined by HS-Lenti Kit-RT assay (Cavidi Tech AB, Uppsala, Sweden) according to the manufacturer's specifications.
Cells and culture conditions
Determination of vector titers
Lentiviral transduction of human cell lines
Exponentially growing hematopoietic (MT-2, Jurkat, U937, K562, NKL, NK-92, Daudi and T7527) and nonhematopoietic (HeLa and 293T) target cells (2.5 Â 10 5 ) were incubated overnight in 24-well plates, with dilutions of vector stocks to give the indicated multiplicity of infection (MOI) in a final volume of 1 ml of their appropriate medium. Then the cells were washed and further cultured for 48 h. Cells were analyzed for expression of EGFP and supernatants were analyzed for aCEA Â aCD3 diabody by enzyme-linked immunosorbent assay (ELISA), fluorescence-activated cell sorting (FACS) and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and Western blotting using anti-myc mAb. Recombinant aCEA Â aCD3 diabody was purified, as described, 23 from conditioned-medium from HEK 293 cells, stably transfected with an expression plasmid 7 or from 293T cells transduced with dAb.EGFPencoding lentiviral vector. A protease inhibitors cocktail (Sigma Biosciences) was added to the medium in order to reduce proteolysis. The medium was concentrated (10 Â ) with a 10 000 MWCO Vivaflow 50 filter (Vivascience AG, Germany), dialyzed against phosphate-buffered saline (PBS) (pH 7.4) and loaded onto a HisTrap HP 1 ml column (Amersham Biosciences, Uppsala, Sweden).
Lentiviral transduction of human primary PBLs
Human PBLs were isolated from the buffy coat fraction of healthy volunteers' peripheral blood by densitygradient centrifugation. Cells were stimulated with plastic immobilized anti-CD3 (100 ng/ml) and anti-CD28 (1 mg/ ml) mAbs in the presence of 50 U/ml IL-2, for 2-3 days. Afterwards, cells were placed in wells coated with Retronectin (10 mg/cm 2 ) and infected with EGFP or dAb-EGFP viral stocks (MOI ¼ 20) for 4 h at 371C and 5% CO 2 . Half the medium was then replaced with fresh medium and cultures were incubated overnight at 371C and 5% CO 2 . The same procedure was repeated once again. After 48 h the cells were expanded for 3 additional days under the same conditions and then with 50 U/ml IL-2 for additional 7 days. The 3-day anti-CD3/anti-CD28 stimulation cycle was repeated every 7 days. The phenotype of PBLs before and after culture was determined by flow cytometry.
Flow cytometry
For phenotypic analysis cells were treated with appropriate dilutions of PE-and ECD-conjugated mAbs for 30 min at 41C. Treatment with the relevant nonspecific PE-and ECD-conjugated Ab served as staining control. The expression of CD66e on HeLa, and HeLa CEA cells and the binding of the secreted aCEA Â aCD3 diabody to CD3 þ cells was studied as previously described. 24 As second-step reagents, anti-myc antibodies and fluorescein isothiocyanate-labeled goat antimouse IgG antibodies (Sigma BioSciences) were used. All samples were fixed in 2% formaldehyde and analyzed using an EPICS XL flow cytometer (Coulter Electronics, Hialeah, FL). Acquisition was set for 10000 events per sample. Forward and side scatter are used to exclude debris and dead cells. Animal studies HCT-116 tumor cells (2 Â 10 6 per animal) and EGFP or dAb-EGFP infected PBLs were mixed in a proportion of 1:1. The cells were mixed 2:1 (vol/vol) with Matrigel (Becton Dickinson, Bedford, MA) and injected subcutaneously into the dorsal space of 5-week-old female athymic nude mice (Harlan Ibe´rica, Barcelona, Spain). Tumor volumes were determined at various time-points; the formula: width 2 Â length Â 0.52 for approximating the volume of a spheroid was applied. All mice were handled in accordance with the guidelines of the Department of Health and Human Services.
T-cell proliferation assay
Results
Construction of a tricistronic lentiviral vector for the expression of a bispecific aCEA Â aCD3 diabody We generated the HIV-1-based lentiviral vector pRRL.dAb.IRES.EGFP (abbreviated as dAb.EGFP; Figure 1a ) containing a bispecific aCEA Â aCD3 twochain diabody. 8 The genes of the tricistronic cassette (diabody chain 1 (VH MFE23 -VL OKT3 ), diabody chain 2 (VH OKT3 -VL MF23-His6myc) and EGFP) were linked by two IRES sequences from the encephalomyocarditis virus (EMCV) and expression of the cassette was driven by the CMV promoter. The vector was pseudotyped by the VSV G envelope protein (VSV-G). It was found that dAb.EGFP can be packaged into lentiviral particles as efficiently as the control vector pRRL.IRES.EGFP (Figure 1b) , as demonstrated by the high-titer vector preparations obtained for these vectors. The dAb.EGFP particles have RT-specific activity (435 pg/ml) comparable to that of EGFP virions (421 pg/ml).
Non-hematopoietic human 293T (data not show) and HeLa ( Figure 2 
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analyzed by electrophoresis on 12% SDS-PAGE. Under these conditions, the diabody was resolved into two protein bands corresponding to the calculated Mr of 28 300 for chain 1 and 31 100 for chain 2 (Figure 2b , left panel). In the Western blot analysis, the anti-myc mAb detected the 31.1 kDa band corresponding to the myctagged chain 2 (Figure 2b right panel) . Similar bands were found in conditioned-medium from HEK 293 cells stably transfected with an expression plasmid 7 containing the aCEA Â aCD3 diabody (data not shown). In the cell culture supernatant of EGFP-transduced cells, no proteins were detected (Figure 2b) . The secreted diabody recognized immobilized CEA, as determined by ELISA (Figure 2c ) and bound specifically to the surface of CD3 þ cells, as assessed by flow cytometry (Figure 2d) .
The percentage of transduced cells and the level of diabody secretion decreased in both cell lines with decreasing MOI (data not shown). Reductions in the levels of EGFP expression ( Figure 2e ) and diabody secretion (Figure 2f ) between days 8 and 15 were observed. The reduction was not associated with cell death, suggesting that toxicity is not a major cause for the loss in transduced cells. Haas et al. showed that after transduction with HIV-1 vectors, the contribution of episomal, nonintegrated vector forms and pseudotransduction of EGFP positivity was undetectable by 14 days post-transduction. 10 Functional diabody was detectable in conditioned-medium from cells grown for several weeks with little difference between days 15 and 30 (Figure 2f ).
Transduction of human hematopoietic cell lines
We compared a panel of hematopoietic cell lines for efficiency of transduction by the dAb.EGFP lentiviral vector. At a MOI of 10, after one single round of infection, the erythromyeloid cell line K562, the myeloid cell line U937, the B cell lines Daudi and T7527 (EBV-LCL), the NK cell lines NKL and NK-92 and the T-cell lines Jurkat and MT-2 were transduced, at levels ranging from 7 to 71% EGFP þ cells (Figure 3a) . Secretion of aCEA Â aCD3 diabody into the cell culture supernatant was assayed 5 days after transduction. Diabody activity was detectable in the conditioned-culture supernatant of all cell lines tested, with the highest level obtained in T-cell (Figure 3b ). These results are not concordant with our previous observations in T-cell lines stably transfected with plasmid DNA, 7 where no aCEA Â aCD3 activity was detected in conditioned-culture supernatant. The difference could be attributable to variations in the relative levels of diabody gene expression obtained with viral and nonviral systems. Cells transduced with EGFP vectors did not produce any detectable aCEA Â aCD3 diabody lines (Figure 3b) . The gene-modified T-cell lines produced biologically active diabody in a dose-dependent (MOI) manner (data not shown) and the expression was stable for several weeks (data not shown). 
Transduction of human PBLs
þ lymphocytes was significantly lower. EGFP expression was maintained for at least 30 days in culture (Figure 4c ). Functional aCEA Â aCD3 diabody was detected in conditioned-medium from PBLs infected with dAb.EGFP (Figure 4d and e), ranging from 1 mg/ml Â 10 5 cells/72 h at day 7 to 0.6 mg/ml Â 10 5 cells/72 h at day 30. The secreted aCEA Â aCD3 diabody had the expected molecular weight (Figure 4f ) and showed high stability under physiological conditions (data not shown). 
Lymphocyte activation and induction of cytotoxicity
To assess the effectiveness of locally secreted aCEA Â aCD3 diabody in providing activation signals from cellular antigen to primary T lymphocytes, PBLs infected with either EGFP
Discussion
In vivo production of therapeutic Abs by genetically engineered cells may advantageously replace injection of purified Abs in cancer treatment. 6 In situ expression potentially circumvents problems of tumor penetration, short serum half-life and even poor specificity. The feasibility of in vivo production and systemic delivery of Abs by different cells has now been demonstrated using different techniques, such as ex vivo genetically modified autologous cells and in vivo gene transfer using viral vectors. 5 Indeed, in vivo secretion of either single-chain Ab fragments (scFv) or bispecific diabodies reduced tumor growth in mice. 7, 11, 12 We have shown that human cells can be genetically modified to secrete functionally active aCEA Â aCD3 diabody enabling primary T lymphocytes to proliferate and kill CEA-expressing human cancer cells. 7 This study was designed to evaluate lentiviral gene transfer for long-term stable expression of a bispecific diabody in primary human hematopoietic cells. Lentiviral vectors can deliver large transgene sequences to a variety of dividing and nondividing cells, including early progenitors and terminally differentiated cells such as macrophages and lymphocytes. 13 In addition, lentiviral vectors promise to be of lower risk for insertional oncogenesis than conventional oncoretroviral vectors.
14 Therefore, we constructed a polycistronic HIV-1-based vector expressing an aCEA Â aCD3 two-chain diabody and the EGFP via IRESs. We first transduced different hematopoietic cell lines with the diabody-encoding vector.
In all hematopoietic cell lines tested, secretion of functional diabody was detected. Interestingly, T-cell lines were shown to secrete the highest levels of aCEA Â aCD3 diabody. The differences in diabody secretion between transduced hematopoietic cell lines appeared to depend more on the transduction efficacy than on factors related to the cell lineage.
The transduction efficiency of PBLs with the VSV-G pseudotyped HIV vector increased linearly with increasing MOIs to a maximum of approximately 35% at an MOI of 20. VSV-G pseudotyped lentivirus present significant advantages in that VSV-G receptor is ubiquitously expressed, giving the vector a broad host-cell range. [15] [16] [17] [18] However, we found that most transduced EGFP-positive cells were CD3 þ CD4 þ T lymphocytes the primary hosts for HIV. Functional aCEA Â aCD3 diabodies were detectable in conditioned-medium from lentivirus infected PBL grown for several weeks. The level reached was sufficient to efficiently activate primary T cells to proliferate and eliminate CEA-expressing tumor cells in vivo. Intratumoral secretion of aCEA Â aCD3 diabodies by gene-modified PBLs significantly reduced the disease burden in an antigen-specific manner. This result is encouraging as it suggest that fewer cells may be required in a clinical situation.
In addition to representing one-step treatment, this approach represent an attractive method for easy, inexpensive and efficient long-term in vivo production of the activating diabody. Furthermore, the highly tumorsite-restricted activation and induction of T-cell cytotoxicity would decrease toxicity inherent to systemic T-cell activation and increase tumoricidal activity by focusing it on the tumor site. Autocrine secretion of tumor-specific diabodies by tumor-infiltrating T lymphocytes offers advantages over current antigen-selective strategies (e.g. systemic administration of purified BsAb and the grafting of T lymphocytes with CIR genes). Prolonged in situ expression of diabody molecules would provide time for tumor-resident T lymphocytes to proliferate and attack the tumor. Recruitment is not restricted to gene-modified cells (e.g. in the CIR approach). The recruitment of both gene-modified (cis-recruitment) and nonmodified (transrecruitment) targeted effectors, present at the tumor site, would amplify the effector response.
In conclusion, in this study we demonstrate for the first time the usefulness of HIV-1-based lentiviral vectors for sustained expression of recombinant bispecific diabody in human primary peripheral blood T lymphocytes and open the way for a new cancer gene therapy strategy. The use of a single-cell population as producer and effector will significantly simplify their development and bodes well for an application in a clinical setting.
